At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Plenty of genetic risk factors for sporadic ALS are still waiting to be found, according to a new meta-analysis of GWAS data.
Novartis to Partner with Banner Health on ApoE4 Prevention Trial Crenezumab Disappoints in Phase 2, Researchers Remain Hopeful Alzheimer’s Disease: In the Eye of the Patient? References and Thresholds—Amyloid Imaging Protocols Debated at AAIC Anti-Amyloid ...
Heart-healthy foods containing omega-3 fatty acids, like salmon, slash risk of developing ALS by one-third.
The enzyme PARC acts as a survival factor in damaged neurons and cancer cells by targeting a pro-apoptotic protein for destruction.